DRI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Darden Restaurants Inc (DRI) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown solid revenue growth and received positive analyst ratings, the recent decline in net income, EPS, and gross margin, combined with hedge fund selling and neutral insider activity, suggests a cautious approach. Additionally, the technical indicators do not signal a strong entry point, and there are concerns about potential headwinds from GLP-1 drug adoption impacting the dining industry. Holding off on a purchase is recommended until clearer positive momentum or a better entry point emerges.
The MACD is negatively expanding (-0.489), indicating bearish momentum. RSI is at 41.408, which is neutral but leaning towards oversold territory. Moving averages are converging, showing no clear trend. The stock is trading below the pivot point (202.391), with key support at 196.049 and resistance at 208.732. Overall, the technical indicators suggest a weak trend with no strong buy signal.
Analysts have raised price targets, with most maintaining Buy or Outperform ratings.
Strong Q3 revenue growth of 5.93% YoY, exceeding expectations.
Encouraging Q4 guidance and market share gains in flagship brands like LongHorn.
Hedge funds are significantly selling, with a 1366.73% increase in selling activity.
Net income, EPS, and gross margin have all declined YoY in Q
JPMorgan's projection of reduced dining frequency due to GLP-1 drug adoption could impact future growth.
In Q3 2026, revenue increased by 5.93% YoY to $3.345 billion. However, net income dropped by 5.13% YoY to $306.8 million, EPS declined by 3.28% YoY to $2.65, and gross margin decreased by 0.50% YoY to 17.97%. While revenue growth is strong, profitability metrics have weakened.
Analysts are optimistic, with multiple firms raising price targets recently. BofA raised its target to $272, Citi to $238, and Barclays to $232, among others. Most analysts maintain Buy or Outperform ratings, citing strong revenue growth and market share gains. However, some concerns about margin risks and challenging top-line comparisons persist.
